Multiplikator forward rega marang pendapatan: Actuate Therapeutics Inc. (ACTU)

Logo korporat perusahaan Actuate Therapeutics Inc. (ACTU)

The market trend for Actuate Therapeutics, Inc. (ACTU) is driven by extreme regulatory threats during the early stages of clinical trials. Analyzing the company's expected P/S chart on GURU.Markets, we see that represents the final metric reading. Growth potential is based on the launch of eladrasib for glioblastoma therapy; however, the lack of revenue and reliance on speculative capital create significant risks for investors.

ACTU (actuatetherapeutics.com) riwayat Multiplikator Forward P/S saka 04.07.2022 nganti 16.11.2026

Rincian analitis perusahaan Actuate Therapeutics, Inc. (ACTU)

- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
Analisis wiwitan perusahaan:Actuate Therapeutics, Inc (ACTU)
Produk sing diprodhuksi Actuate Therapeutics Inc

The margin of safety assessment for Actuate Therapeutics, Inc. (ACTU) is based on the ratio of market value to expected annual sales, which currently stands at . By analyzing the forward P/S indicator, an investor determines the degree of overvaluation of the capitalization relative to revenue forecasts, which is critically important for a biopharmaceutical company developing innovative GSK-3 beta inhibitors to combat resistant forms of metastatic cancer.

Pesaing wigati

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CTOR|Rasio rega marang prakiraan pendapatan TuHURA Biosciences Inc.|TARA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|Rasio kapitalisasi marang dodolan sing dikarepake Aadi Bioscience|Rasio rega marang prakiraan pendapatan TScan Therapeutics Inc TCRX|CSBR: Kapitalisasi marang prakiraan pendapatan|XBIT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CVM (cel-sci.com)|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ANL (Adlai Nortye)|Rasio rega marang prakiraan pendapatan Veru Pharma (VERU)|Multiplikator Forward P/S Tempest Tx (TPST)|Rasio rega marang prakiraan pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S